Fasikl's Felix NeuroAI Wristband Outperforms Sham in Essential Tremor Study

Fasikl’s Felix NeuroAI Wristband Outperforms Sham in Essential Tremor Study

Fasikl’s NeuroAI™ Wristband Demonstrates Breakthrough Results in Pivotal TRANQUIL Study for Essential Tremor Fasikl, a pioneering neuro-AI company at the forefront of integrating bioelectronic medicine with artificial intelligence, today announced that its landmark TRANQUIL study met its primary endpoint. The…

Read MoreFasikl’s Felix NeuroAI Wristband Outperforms Sham in Essential Tremor Study

Sentynl Therapeutics Unveils First Clinical Evidence Supporting NULIBRY® for Molybdenum Cofactor Deficiency Type A

Sentynl Therapeutics Unveils First Clinical Evidence Supporting NULIBRY® for Molybdenum Cofactor Deficiency Type A Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company wholly owned by Zydus Lifesciences, Ltd., has announced the publication of groundbreaking clinical data regarding NULIBRY® (fosdenopterin) in the…

Read MoreSentynl Therapeutics Unveils First Clinical Evidence Supporting NULIBRY® for Molybdenum Cofactor Deficiency Type A

Viz.ai Wins 2025 Edison Award™ for Machine Learning Innovation for Third Year

Viz.ai Wins 2025 Edison Award™ for Machine Learning Innovation for Third Year Viz.ai, a leader in artificial intelligence (AI)-powered disease detection and intelligent care coordination, has announced its recognition as an Award Winner in the 2025 Edison Awards, marking the…

Read MoreViz.ai Wins 2025 Edison Award™ for Machine Learning Innovation for Third Year

ABEC Unveils Single-Use Bioreactor for Cell Therapy Manufacturing

ABEC Unveils Single-Use Bioreactor for Cell Therapy Manufacturing ABEC, a global leader in engineered solutions for biotechnology manufacturing, has introduced its Advanced Therapy Bioreactor (ATB™), a groundbreaking platform designed to advance the manufacturing of advanced therapy medicinal products (ATMPs). The…

Read MoreABEC Unveils Single-Use Bioreactor for Cell Therapy Manufacturing